The University of Alberta has been granted two new patents in the United States, as well as its first patent in the European Union, for technology to treat multiple sclerosis, according to BioMS Medical Corp.
BioMS Medical Corp., through a subsidiary, licenses these patents on an exclusive worldwide basis from the university.
In total, 17 patents have been granted to the university in 13 countries worldwide, including New Zealand, the Russian Federation, the United Kingdom, Australia, Belgium, Ireland, Italy, the Netherlands, Sweden, Switzerland, Spain and Hungary.
Additional patents are pending in another 18 countries.
These patents cover the use of the company’s MBP8298 synthetic peptide technology for the treatment of multiple sclerosis (MS), which has been used in Phase I and Phase II human clinical trials since 1992.
Kevin Giese, president of BioMS Medical, said: “Patent protection is vitally important to ensuring the future commercial value for our MBP8298 technology.”
